Gorczyca-Głowacka Iwona, Nawacki Łukasz, Kołomańska Magdalena, Mazurkiewicz Robert, Niżnik Marcin, Ratnicki Krzysztof, Czerniak Małgorzata, Myrcha Piotr, Bękarski Maciej, Rocha-Neves Joao, Pereira-Macedo Juliana, Mitura Kryspin, Kacprzak Laura, Pajer Małgorzata, Richter Piotr, Rapacz Kamil, Sroczyński Maciej, Szmit Mateusz, Głuszek Stanisław
Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Independent Public Health Care Center of the Ministry of Internal and Administration, Gdańsk, Poland.
Clin Exp Hepatol. 2025 Jun;11(2):160-168. doi: 10.5114/ceh.2025.151805. Epub 2025 Jun 9.
Data concerning the clinical manifestation and outcomes of lean metabolic dysfunction-associated steatotic liver disease (MASLD) are scarce and inconsistent. The aim of the study was to evaluate the clinical characteristics of MASLD and predictors of its occurrence.
The study included patients from the Polish Gallstone Surgery Registry diagnosed with MASLD according to the current criteria.
Among 3,419 patients, MASLD was diagnosed in 24.2%. Lean MASLD was diagnosed in 11.3% of patients with MASLD. Independent predictors of lean MASLD were atherogenic dyslipidaemia (OR = 94.16, CI: 45.54-197.71, < 0.0001), diabetes mellitus or prediabetes conditions (OR = 9.26, CI: 4.42-19.38, < 0.0001) and hypertension (OR = 2.97, CI: 1.38-6.41, = 0.0054).
Lean MASLD is not a rare form of the disease, and in the lean MASLD group there are patients with a high rate of metabolic abnormalities which may significantly increase cardiovascular risk and the risk of MASLD progression.
关于瘦型代谢功能障碍相关脂肪性肝病（MASLD）临床表现及预后的数据稀少且不一致。本研究旨在评估MASLD的临床特征及其发生的预测因素。
本研究纳入了波兰胆结石手术登记处中根据现行标准诊断为MASLD的患者。
在3419例患者中，24.2%被诊断为MASLD。在MASLD患者中，11.3%被诊断为瘦型MASLD。瘦型MASLD的独立预测因素为致动脉粥样硬化性血脂异常（OR = 94.16，CI：45.54 - 197.71，< 0.0001）、糖尿病或糖尿病前期状态（OR = 9.26，CI：4.42 - 19.38，< 0.0001）以及高血压（OR = 2.97，CI：1.38 - 6.41，= 0.0054）。
瘦型MASLD并非该疾病的罕见形式，且在瘦型MASLD组中，患者存在高比例的代谢异常，这可能会显著增加心血管风险以及MASLD进展的风险。
